Developer docs
API playgroundTry for free, no card

Search company profiles

Bell Pharmaceuticals & Cosmetics

Full company profile

uuid02mirqi

Namestring
Bell Pharmaceuticals & Cosmetics
Legal namestring
Bell Pharmaceuticals & Cosmetics Private Limited
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Bell Pharmaceuticals & Cosmetics Private Limited is an Indian privately-held contract development and manufacturing organization (CDMO) headquartered in Siddipet, Telangana, operating 15 advanced manufacturing facilities that produce pharmaceutical formulations, nutraceuticals, cosmetics, and dermatology products on behalf of Indian and multinational clients. The company was established in 2010 as Bell Pharmaceuticals Ltd, expanded into pharmaceutical manufacturing with Plant 1 in 2015, and now claims to contribute roughly 9–10% of India's total medicinal requirements while serving 500+ clients globally including named enterprise customers such as Abbott. Its technology stack includes Novel Drug Delivery Systems (N.D.D.S), differentiated dosage formats (gummies, mouth-melt tablets, effervescent sachets), a centralized stability center following ICH guidelines, and the ARKA 24,000 sq ft NABL-accredited analytical laboratory in Hyderabad for chemical, microbiological, and stability testing.

The company's revenue model is built on B2B contract manufacturing services — including Contract Research and Manufacturing Services (CRAMS), technology transfer, loan licensing, contract development, and technical collaborations — priced on a custom quote basis per client requirement, formulation complexity, and volume, typically structured as multi-year contracts. Customer segments span pharmaceutical companies (primary), nutraceutical companies, and cosmetics and dermatology brands, served through direct enterprise sales and export channels across India, Brazil, Nigeria, Ghana, and Malawi. Certifications are a core commercial asset: WHO-GMP, State GMP, ISO 9001:2008, ISO 14001:2004, DSIR-approved R&D, US-NSF (nutraceuticals), NABL (testing), DCGI and FSSAI approvals, with ANVISA, NAFDAC, FDB, PMPB, EU GMP, and PIC/S GMP actively in progress. Leadership is founder-controlled, with Y Madhusudhan Reddy as Chairman & MD, Dr K Someshwar as Director & CEO, and Satwik Reddy Legala as a recent investor. The company operates two wholly-owned subsidiaries: Bell Nutravedics Ltd (nutraceuticals, US-NSF approved) and ARKA Pharmaceutical Testing Labs (NABL accredited).

Short descriptiontext

Bell Pharmaceuticals & Cosmetics is an Indian CDMO operating 15 manufacturing facilities that produce pharmaceuticals, nutraceuticals, cosmetics, and dermatology products on a contract manufacturing basis for 500+ Indian and multinational pharmaceutical clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSiddipet, India
HQ citystring
Siddipet
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical contract manufacturing, nutraceutical manufacturing services, cosmetics contract manufacturing, dermatology product manufacturing, CRAMS services
Industry3 codes
PRIMARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Pharmaceutical Contract Manufacturing & CDMO Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Contract Manufacturing Services (CRAMS)
TypeManaged Services
Description

Contract Research and Manufacturing Services providing end-to-end services for drug development, manufacturing, and supply chain management. Services include Technology Transfer, Loan License, Contract Development, Novel Drug Delivery Systems, and Technical Collaboration/Joint Ventures.

bellpharmagroup.com
2Pharmaceutical Formulations
TypeOne Time License
Description

Manufacturing and supplying pharmaceutical formulations in various dosage forms including tablets, capsules, syrups, ointments under customer brand names

bellpharmagroup.com
3Nutraceutical Products
TypeOne Time License
Description

Production of dietary supplements, herbal/ayurvedic formulations, veterinary feed supplements for various market segments

bellpharmagroup.com
4Cosmetics & Dermatology Products
TypeOne Time License
Description

Manufacturing of cosmetic and dermatological products including hair care, personal care, and skincare products with cruelty-free testing methods

bellpharmagroup.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components7 values
Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Others
Pricing details1 tier
1Custom contract manufacturing pricing based on volume, formulation complexity, and regulatory requirements
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based pricing tailored to specific client needs, volume requirements, and regulatory certifications

bellpharmagroup.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Bell Nutravedics Ltd
Description

Subsidiary entity specializing in nutraceuticals, food supplements, herbal and ayurvedic formulations, and veterinary feed supplements with US-NSF approved facility.

bellpharmagroup.com
Core offering1 text field

Bell Pharmaceuticals & Cosmetics operates as a Contract Development and Manufacturing Organization (CDMO) producing pharmaceutical formulations (tablets, hard/soft gelatin capsules, syrups, ointments, sachets), nutraceutical and Ayurvedic formulations, veterinary feed supplements, and cosmetics/dermatology products across 15 advanced manufacturing facilities. It also provides end-to-end Contract Research and Manufacturing Services (CRAMS) including technology transfer, loan licensing, contract development, Novel Drug Delivery Systems (N.D.D.S), technical collaborations, and NABL-accredited analytical testing through its ARKA laboratory.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 9-10% of India's total medicinal requirements met by Bell
+2 more records
Product overview1 text field

Bell Pharmaceuticals & Cosmetics is a contract development and manufacturing organization (CDMO) offering integrated pharmaceutical, nutraceutical, and cosmetics manufacturing services. The portfolio includes core manufacturing of pharmaceuticals (tablets, capsules, syrups, ointments), nutraceuticals (supplements in various dosage forms including gummies and effervescent tablets), and cosmetics/dermatology products across multiple branded ranges. Services include Contract Research & Manufacturing Services (CRAMS), Novel Drug Delivery Systems (N.D.D.S), and NABL-accredited testing laboratory services under the ARKA brand. The company operates 15 advanced manufacturing facilities with capabilities spanning pharmaceuticals, nutraceuticals, cosmetics, and dermatology, supported by DSIR-approved R&D facilities.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Multinational Pharmaceutical Companies
Strategic tierCoreTypeOthers
Description

Bell enables production for big multinationals and large pharmaceutical companies. The partnership involves providing end-to-end contract manufacturing services including drug development, technology transfer, and regulatory compliance support. Bell develops innovative, technology-driven products and manufactures them under customer brand names.

bellpharmagroup.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

India-headquartered global CDMO providing API and intermediate manufacturing services with significant scale in contract development and manufacturing for global pharma — directly comparable to Bell's CDMO positioning but operating at much larger scale and primarily in drug substance/API rather than finished dosage forms.

TypeDirect peer
Description

India and global CDMO offering integrated contract development and manufacturing services across drug substance and drug product, including sterile fill-finish — a direct peer to Bell's end-to-end contract manufacturing model, serving multinational pharma clients with multi-site capacity.

3Syngene International
TypeOthers
Description

India's largest listed CRO/CDMO providing contract research, development, and manufacturing services for global pharma and biotech — comparable to Bell's CRAMS offering with a stronger discovery/research tilt but similar international pharmaceutical customer base.

TypeDirect peer
Description

Indian CDMO with contract manufacturing of sterile injectables, APIs, and radiopharma, serving global regulated markets; comparable to Bell in B2B pharma manufacturing and regulatory-driven export work.

TypeBroad incumbent
Description

Large Indian pharmaceutical company with vertically integrated API and finished dosage manufacturing and an expanding third-party contract manufacturing franchise — broader than Bell but overlapping in generic formulation contract manufacturing.

TypeDirect peer
Description

India-based CDMO specializing in complex API and intermediate development and manufacturing for global pharma — comparable to Bell as an Indian CRAMS/CDMO serving multinational pharma clients.

TypeDirect peer
Description

Indian CDMO providing API contract manufacturing, custom synthesis, and formulation services to global pharma — directly comparable to Bell's business model of contract manufacturing for innovator and generic drug companies.

TypeDirect peer
Description

Indian pharmaceutical manufacturer with active contract manufacturing services across APIs and formulations including FDCs and novel drug delivery systems — directly comparable to Bell's FDC and N.D.D.S positioning and Indian-multinational customer mix.

TypeDirect peer
Description

India-based CRO/CDMO offering formulation development, analytical services, and commercial contract manufacturing for global pharma — closely comparable to Bell on CDMO services, formulation R&D, and analytical testing capabilities.

TypeRegional player
Description

Indian pharmaceutical manufacturer and contract manufacturer with formulation production across dosage forms, plus an in-house analytical testing vertical — comparable to Bell as an Indian multi-vertical private CDMO with limited international footprint.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance18 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bell Pharmaceuticals & Cosmetics

Pharmaceutical Contract Manufacturing & CDMO Servicesbellpharmagroup.com

Bell Pharmaceuticals & Cosmetics is an Indian CDMO operating 15 manufacturing facilities that produce pharmaceuticals, nutraceuticals, cosmetics, and dermatology products on a contract manufacturing basis for 500+ Indian and multinational pharmaceutical clients.

What Bell Pharmaceuticals & Cosmetics does

Bell Pharmaceuticals & Cosmetics Private Limited is an Indian privately-held contract development and manufacturing organization (CDMO) headquartered in Siddipet, Telangana, operating 15 advanced manufacturing facilities that produce pharmaceutical formulations, nutraceuticals, cosmetics, and dermatology products on behalf of Indian and multinational clients. The company was established in 2010 as Bell Pharmaceuticals Ltd, expanded into pharmaceutical manufacturing with Plant 1 in 2015, and now claims to contribute roughly 9–10% of India's total medicinal requirements while serving 500+ clients globally including named enterprise customers such as Abbott. Its technology stack includes Novel Drug Delivery Systems (N.D.D.S), differentiated dosage formats (gummies, mouth-melt tablets, effervescent sachets), a centralized stability center following ICH guidelines, and the ARKA 24,000 sq ft NABL-accredited analytical laboratory in Hyderabad for chemical, microbiological, and stability testing.

The company's revenue model is built on B2B contract manufacturing services — including Contract Research and Manufacturing Services (CRAMS), technology transfer, loan licensing, contract development, and technical collaborations — priced on a custom quote basis per client requirement, formulation complexity, and volume, typically structured as multi-year contracts. Customer segments span pharmaceutical companies (primary), nutraceutical companies, and cosmetics and dermatology brands, served through direct enterprise sales and export channels across India, Brazil, Nigeria, Ghana, and Malawi. Certifications are a core commercial asset: WHO-GMP, State GMP, ISO 9001:2008, ISO 14001:2004, DSIR-approved R&D, US-NSF (nutraceuticals), NABL (testing), DCGI and FSSAI approvals, with ANVISA, NAFDAC, FDB, PMPB, EU GMP, and PIC/S GMP actively in progress. Leadership is founder-controlled, with Y Madhusudhan Reddy as Chairman & MD, Dr K Someshwar as Director & CEO, and Satwik Reddy Legala as a recent investor. The company operates two wholly-owned subsidiaries: Bell Nutravedics Ltd (nutraceuticals, US-NSF approved) and ARKA Pharmaceutical Testing Labs (NABL accredited).

Bell Pharmaceuticals & Cosmetics firmographics

Firmographics
Name
Bell Pharmaceuticals & Cosmetics
Legal name
Bell Pharmaceuticals & Cosmetics Private Limited
Website
https://bellpharmagroup.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
51–100 employees
Short description
Bell Pharmaceuticals & Cosmetics is an Indian CDMO operating 15 manufacturing facilities that produce pharmaceuticals, nutraceuticals, cosmetics, and dermatology products on a contract manufacturing basis for 500+ Indian and multinational pharmaceutical clients.
Ownership category
akta.pro rank

Bell Pharmaceuticals & Cosmetics industry classification

Industry
Product category
Pharmaceutical Contract Manufacturing & CDMO Services
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Pharmaceutical contract manufacturing
  • Nutraceutical manufacturing services
  • Cosmetics contract manufacturing
  • Dermatology product manufacturing
  • CRAMS services

Where Bell Pharmaceuticals & Cosmetics is headquartered

Location

Headquarters

HQ city
Siddipet
HQ country
India
HQ region
Asia

Offices2 records

Markets served

Bell Pharmaceuticals & Cosmetics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Others

Revenue model

  1. Contract Manufacturing Services (CRAMS): Contract Research and Manufacturing Services providing end-to-end services for drug development, manufacturing, and supply chain management. Services include Technology Transfer, Loan License, Contract Development, Novel Drug Delivery Systems, and Technical Collaboration/Joint Ventures.
  2. Pharmaceutical Formulations: Manufacturing and supplying pharmaceutical formulations in various dosage forms including tablets, capsules, syrups, ointments under customer brand names
  3. Nutraceutical Products: Production of dietary supplements, herbal/ayurvedic formulations, veterinary feed supplements for various market segments
  4. Cosmetics & Dermatology Products: Manufacturing of cosmetic and dermatological products including hair care, personal care, and skincare products with cruelty-free testing methods

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom contract manufacturing pricing based on volume, formulation complexity, and regulatory requirements

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Bell Pharmaceuticals & Cosmetics product offering

Product offering

Core offering

Bell Pharmaceuticals & Cosmetics operates as a Contract Development and Manufacturing Organization (CDMO) producing pharmaceutical formulations (tablets, hard/soft gelatin capsules, syrups, ointments, sachets), nutraceutical and Ayurvedic formulations, veterinary feed supplements, and cosmetics/dermatology products across 15 advanced manufacturing facilities. It also provides end-to-end Contract Research and Manufacturing Services (CRAMS) including technology transfer, loan licensing, contract development, Novel Drug Delivery Systems (N.D.D.S), technical collaborations, and NABL-accredited analytical testing through its ARKA laboratory.

Product overview

Bell Pharmaceuticals & Cosmetics is a contract development and manufacturing organization (CDMO) offering integrated pharmaceutical, nutraceutical, and cosmetics manufacturing services. The portfolio includes core manufacturing of pharmaceuticals (tablets, capsules, syrups, ointments), nutraceuticals (supplements in various dosage forms including gummies and effervescent tablets), and cosmetics/dermatology products across multiple branded ranges. Services include Contract Research & Manufacturing Services (CRAMS), Novel Drug Delivery Systems (N.D.D.S), and NABL-accredited testing laboratory services under the ARKA brand. The company operates 15 advanced manufacturing facilities with capabilities spanning pharmaceuticals, nutraceuticals, cosmetics, and dermatology, supported by DSIR-approved R&D facilities.

Differentiator

Problem solved

Functional benefit

Brands

  • Bell Nutravedics Ltd: Subsidiary entity specializing in nutraceuticals, food supplements, herbal and ayurvedic formulations, and veterinary feed supplements with US-NSF approved facility.

Quantifiable outcome

  • 9-10% of India's total medicinal requirements met by Bell
  • +2 more outcomes

Companies that use Bell Pharmaceuticals & Cosmetics

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Bell Pharmaceuticals & Cosmetics technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Bell Pharmaceuticals & Cosmetics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Multinational Pharmaceutical CompaniescoreOthersBell enables production for big multinationals and large pharmaceutical companies. The partnership involves providing end-to-end contract manufacturing services including drug development, technology transfer, and regulatory compliance support. Bell develops innovative, technology-driven products and manufactures them under customer brand names.

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Bell Pharmaceuticals & Cosmetics competitors and assessment

Company assessment

Broad incumbents

  • Divi's Laboratories: India-headquartered global CDMO providing API and intermediate manufacturing services with significant scale in contract development and manufacturing for global pharma — directly comparable to Bell's CDMO positioning but operating at much larger scale and primarily in drug substance/API rather than finished dosage forms.
  • Aurobindo Pharma: Large Indian pharmaceutical company with vertically integrated API and finished dosage manufacturing and an expanding third-party contract manufacturing franchise — broader than Bell but overlapping in generic formulation contract manufacturing.

Direct peers

  • Piramal Pharma Solutions: India and global CDMO offering integrated contract development and manufacturing services across drug substance and drug product, including sterile fill-finish — a direct peer to Bell's end-to-end contract manufacturing model, serving multinational pharma clients with multi-site capacity.
  • Jubilant Pharmova: Indian CDMO with contract manufacturing of sterile injectables, APIs, and radiopharma, serving global regulated markets; comparable to Bell in B2B pharma manufacturing and regulatory-driven export work.
  • Suven Pharmaceuticals: India-based CDMO specializing in complex API and intermediate development and manufacturing for global pharma — comparable to Bell as an Indian CRAMS/CDMO serving multinational pharma clients.
  • Neuland Laboratories: Indian CDMO providing API contract manufacturing, custom synthesis, and formulation services to global pharma — directly comparable to Bell's business model of contract manufacturing for innovator and generic drug companies.
  • MSN Laboratories: Indian pharmaceutical manufacturer with active contract manufacturing services across APIs and formulations including FDCs and novel drug delivery systems — directly comparable to Bell's FDC and N.D.D.S positioning and Indian-multinational customer mix.
  • Aizant Drug Research: India-based CRO/CDMO offering formulation development, analytical services, and commercial contract manufacturing for global pharma — closely comparable to Bell on CDMO services, formulation R&D, and analytical testing capabilities.

Others

  • Syngene International: India's largest listed CRO/CDMO providing contract research, development, and manufacturing services for global pharma and biotech — comparable to Bell's CRAMS offering with a stronger discovery/research tilt but similar international pharmaceutical customer base.

Regional players

  • Arbro Pharmaceuticals: Indian pharmaceutical manufacturer and contract manufacturer with formulation production across dosage forms, plus an in-house analytical testing vertical — comparable to Bell as an Indian multi-vertical private CDMO with limited international footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Bell Pharmaceuticals & Cosmetics social profiles

Digital presence

Bell Pharmaceuticals & Cosmetics compliance and trust

Trust signal

Compliance18 records

Bell Pharmaceuticals & Cosmetics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bell Pharmaceuticals & Cosmetics leadership team

Management profile

Number of profiles

Profiles6 records

Bell Pharmaceuticals & Cosmetics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Bell Pharmaceuticals & Cosmetics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bell Pharmaceuticals & Cosmetics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bell Pharmaceuticals & Cosmetics

What does Bell Pharmaceuticals & Cosmetics do?

Bell Pharmaceuticals & Cosmetics operates as a Contract Development and Manufacturing Organization (CDMO) producing pharmaceutical formulations (tablets, hard/soft gelatin capsules, syrups, ointments, sachets), nutraceutical and Ayurvedic formulations, veterinary feed supplements, and cosmetics/dermatology products across 15 advanced manufacturing facilities. It also provides end-to-end Contract Research and Manufacturing Services (CRAMS) including technology transfer, loan licensing, contract development, Novel Drug Delivery Systems (N.D.D.S), technical collaborations, and NABL-accredited analytical testing through its ARKA laboratory.

Is Bell Pharmaceuticals & Cosmetics a public or private company?

Bell Pharmaceuticals & Cosmetics is a private company. It is currently operating.

When was Bell Pharmaceuticals & Cosmetics founded?

Bell Pharmaceuticals & Cosmetics was founded in 2010. It employs 51 to 100 people.

Where is Bell Pharmaceuticals & Cosmetics based?

Bell Pharmaceuticals & Cosmetics is headquartered in Siddipet, India, in the Asia region.

How does Bell Pharmaceuticals & Cosmetics make money?

Four revenue lines are on record. Contract Manufacturing Services (CRAMS) is the primary driver. The others are pharmaceutical Formulations, nutraceutical Products and cosmetics & Dermatology Products.

Who are Bell Pharmaceuticals & Cosmetics's main competitors?

Broad incumbents on record are Divi's Laboratories and Aurobindo Pharma. Direct peers are Piramal Pharma Solutions, Jubilant Pharmova, Suven Pharmaceuticals, Neuland Laboratories, MSN Laboratories and Aizant Drug Research. Syngene International is listed as an others. Arbro Pharmaceuticals is listed as a regional player.

Does Bell Pharmaceuticals & Cosmetics have an API?

No public API is recorded for Bell Pharmaceuticals & Cosmetics.

What industry is Bell Pharmaceuticals & Cosmetics in?

Bell Pharmaceuticals & Cosmetics's product category is Pharmaceutical Contract Manufacturing & CDMO Services. Its primary akta.pro industry code is HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO), with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales